Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.54 |
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281598 | 0.77 | SMN1; SMN2 (0.48) | RAB9ANPC1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL5269272 | 0.76 | KDM4E (0.55) | RAB9ANPC1CCNA2CDK2CCNA1 | |
| SCHEMBL161227 | 0.74 | NPC1 (0.72) | RAB9ANPC1KDM4ECYP1A2HPGD | |
| SCHEMBL24673320 | 0.73 | NPC1 (0.73) | RAB9ANPC1KDM4ECYP1A2HPGD | |
| SCHEMBL307051 | 0.73 | NPC1 (0.73) | RAB9ANPC1KDM4ECYP1A2HPGD | |
| SCHEMBL5168314 | 0.73 | NPC1 (0.73) | RAB9ANPC1KDM4ECYP1A2HPGD | |
| SCHEMBL23594174 | 0.73 | NPC1 (0.73) | RAB9ANPC1KDM4ECYP1A2HPGD | |
| SCHEMBL8396558 | 0.73 | NPC1 (0.73) | RAB9ANPC1KDM4ECYP1A2HPGD | |
| SCHEMBL12962652 | 0.72 | NPC1 (0.38) | RAB9ANPC1CDK2 | |
| Hydrochloric Acid SCHEMBL3747209 | 0.71 | NPC1 (0.71) | RAB9ANPC1KDM4ECYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | RAB9A 291/4885NPC1 1266/4885CCNA2 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.